Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
15/04/2026 08:13
April 15 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST: ANNOUNCES BFARM APPROVAL OF OPTIMIZED PHASE IB/II STUDY DESIGN Source text: ID:nMFNm3xPj Further company coverage: ISOFOL.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism